A phase 3 trial of Roche’s giredestrant in first-line breast cancer patients has missed its primary endpoint, tarnishing the record of a drug candidate that hit the mark in adjuvant and second-line settings.
- Home |
- Roche’s oral SERD flunks phase 3 trial in 1st-line breast cancer, raising questions of mechanism’s limits
Roche’s oral SERD flunks phase 3 trial in 1st-line breast cancer, raising questions of mechanism’s limits
- March 9, 2026
Recent Posts
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
- Cenovus to build oil sands business via Athabasca acquisition
- Centalion acquires Haynesville gas assets from Silver Hill
